Nifty Healthcare Index News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Fortis Healthcare Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Fortis Healthcare Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news and updates on Nifty Healthcare Index from all sources in a single place.

Load latest

Biocon Ltd.

22 May 2025

335.05

-0.24%

Company Update

Biocon Ltd - 532523 - Company Statement

BSE India

Company Statement

pdf

Sun Pharmaceutical Industries Ltd.

22 May 2025

1671.10

-0.39%

Q4 results today: ITC, Sun Pharma among 165 companies to announce earnings on Thursday

Economic Times

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC's revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.

Sun Pharmaceutical I.. has an average target of 2039.89 from 9 brokers.

Fortis Healthcare Ltd.

22 May 2025

709.40

0.44%

Fortis Healthcare (FORH IN) Q4FY25-Result Update Strong FY26...

Buy: Fortis Healthcare Ltd.

Target

Prabhudas Lilladhar

Fortis Healthcare's (FORH) Q4FY25 EBITDA at Rs4.36bn; up 14% YoY was in line with our estimates. Though hospital margins improved by 170bps/190bps YoY in FY24/FY25, we see further scope for improvement aided by 1) improving case and payor mix, 2) cost rationalization initiatives including divestment of Richmond unit in Bangalore, ramp up of Manesar unit and 3) new brownfield bed additions. Fortis consolidated 89.2% stake in Agilus in Jan'25. We expect...

Number of FII/FPI investors increased from 400 to 452 in Mar 2025 qtr.

Max Healthcare Institute Ltd.

22 May 2025

1150.30

2.23%

Max Healthcare Institute (MAXHEALT IN) Q4FY25 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Dwarka unit achieved break-even vs loss of Rs50mn in Q3. YoY to Rs 6.32bn; in line with our estimates. The company showed phenomenal additions. We expect pick-up in the growth momentum given 1) strong expansion plans (+3500 additional beds over FY24-27E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and...

Max Healthcare Institute Ltd.'s price crossed above 30Day SMA today

Mankind Pharma Ltd.

22 May 2025

2468.20

0.02%

Higher marketing/promotional costs drive a miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.

Mankind Pharma Ltd. is trading above its 100 day SMA of 2464.5

Mankind Pharma Ltd.

21 May 2025

2468.20

0.02%

Earnings Call

Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Investor Conference Call for Q4 & FY25 - Audio Recording

pdf

Fortis Healthcare Ltd.

21 May 2025

709.40

0.44%

IHH's move to seek increased damages may not affect Fortis expansion plans

Business Standard

Analysts say IHH's reputational harm claim in Japan won't impact Fortis's Indian operations; litigation continues over stalled open offer and regulatory hurdles

Fortis Healthcare Ltd. has gained 49.32% in the last 1 Year

Mankind Pharma Ltd.

21 May 2025

2468.20

0.02%

Mankind Pharma Results Earnings Call for Q4FY25 & Full Year

Conference Call with Mankind Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Syngene International Ltd.

21 May 2025

649.85

0.51%

Company Update

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the details of the meeting to be held with the Analyst/Institutional Investor.

pdf

Max Healthcare Institute Ltd.

21 May 2025

1150.30

2.23%

Company Update

Max Healthcare Institute Ltd - 543220 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication pertaining to Financial Results for the quarter and financial year ended March 31, 2025

pdf

Nifty Healthcare Index PB	6.0
Nifty Healthcare Index PE	36.2
Nifty Healthcare Index DIV	0.5
Nifty Healthcare Index EPS	384.1